Skip to the answer

Buprenorphine / Naloxone Uses, Dosage, Side Effects and Interactions

Brand names
Suboxone

Suboxone was the first buprenorphine / naloxone product the FDA approved, in October 2002. An FDA-approved generic with the same active ingredients is listed.

Zubsolv

Zubsolv came 10 years after Suboxone (July 2013) as a sublingual tablet. The FDA rates no generic as a substitute for it.

First generic of Zubsolv: our estimate, September 2030

Bunavail

Bunavail came 11 years after Suboxone (June 2014) as a buccal film, a form not listed for Suboxone. The FDA now lists it as discontinued; generic buprenorphine / naloxone is still listed.

Buprenorphine / Naloxone is a combination medicine placed under the tongue (or, for the film, inside the cheek) to treat opioid dependence, as part of a full treatment plan with counseling.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About Buprenorphine / NaloxoneType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Buprenorphine / Naloxone in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Buprenorphine / naloxone (Suboxone and others) is a widely used first-line treatment for opioid dependence that pairs buprenorphine, which only partly switches on opioid receptors to ease withdrawal and cravings, with naloxone, which does little under the tongue but discourages injecting it; it is meant to be used with counseling, has been on the U.S. market since about 2010, and has FDA-approved generics listed. Most people tolerate it well once the dose is settled, and headache, nausea, constipation, sweating and trouble sleeping are what people usually notice. The serious risk is slowed, shallow breathing, especially when it is mixed with alcohol, benzodiazepines or other sedating drugs.

Key Takeaways From the HelloPharmacist Team

  • Let each dose dissolve fully under your tongue, or the film inside your cheek, as a single daily dose.
  • Hold your first dose until clear withdrawal symptoms have started, as your prescriber directs, since dosing too early can bring on sudden withdrawal.
  • Lock it away from children and keep naloxone, the overdose rescue medicine, at home, calling 911 even after giving it.
  • Do not stop it suddenly, since withdrawal can follow; your prescriber will taper the dose gradually when the time comes.

How we write and review this content: our editorial policy

Buprenorphine / Naloxone by the Numbers

Strengths
12
across 2 forms
Makers and packagers
29
Earliest FDA record
2010
Rank by Medicaid prescriptions
#21 of 1,682 drugs
More prescriptions than 98% of the 1,682 drugs we measure
6.98 million prescriptions, Q1–Q4 2025

Patient Information Guide for Buprenorphine / Naloxone

What It’s Used For

Buprenorphine / Naloxone treats opioid dependence, always alongside counseling and psychosocial support.

  • Buprenorphine and naloxone sublingual tablets: maintenance treatment of opioid dependence.
  • Buprenorphine and naloxone sublingual film (including Suboxone film, used sublingually or buccally): treatment of opioid dependence.
  • Zubsolv (orally disintegrating sublingual tablet): treatment of opioid dependence.

How It Works

Buprenorphine partially activates the mu-opioid receptor and blocks the kappa-opioid receptor. This eases withdrawal while limiting the full effects of stronger opioids. Naloxone is a strong opioid blocker. It does little when the medicine is taken under the tongue, but it can bring on withdrawal if the product is injected by someone dependent on full opioids.

Drug Class

Drug Class

  • Partial Opioid Agonist from buprenorphine
  • Opioid Antagonist from naloxone
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class. Buprenorphine / Naloxone has two active ingredients, so each class says which one it comes from.

Drug Class

Established Pharmacologic Class (EPC)
  • Partial Opioid Agonist from buprenorphine
  • Opioid Antagonist from naloxone

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • Partial Opioid Agonists from buprenorphine
  • Opioid Antagonists from naloxone

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Buprenorphine / Naloxone in the FDA’s index.

From our Patient Information GuideBuprenorphine partially activates the mu-opioid receptor and blocks the kappa-opioid receptor. This eases withdrawal while limiting the full effects of stronger opioids. Naloxone is a strong opioid blocker. Read How Buprenorphine / Naloxone Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Buprenorphine / Naloxone in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Oripavine derivatives from buprenorphine
  • Drugs used in opioid dependence from buprenorphine
  • Peripheral opioid receptor antagonists from naloxone

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

This medicine is taken once a day, under the tongue. The film can also be used inside the cheek.

  • Treatment is started when clear withdrawal signs are present, to avoid triggering withdrawal.
  • The film and Zubsolv are given in divided doses at the start of treatment.
  • Your dose is then adjusted to keep you in treatment and control withdrawal symptoms.
  • Follow your prescriber and the label for your exact instructions.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Buprenorphine / Naloxone Sublingual Tablets

Opioid dependence
Adults · Maintenance dose Dose 4/1 mg Highest dose 24/6 mg

Step by step

  1. Generally in the range of 4 mg/1 mg buprenorphine/naloxone to 24 mg/6 mg buprenorphine/naloxone per day, as a single daily dose
  2. Adjusted in increments/decrements of 2 mg/0.5 mg or 4 mg/1 mg
  3. Dosages higher than 24 mg/6 mg have not been demonstrated to provide any clinical advantage
Adults · Target dose Usual dose 16 mg/4 mg once a day
  • 16 mg/4 mg buprenorphine/naloxone/day as a single daily dose
Adults dependent on short-acting opioids such as heroin · Zubsolv 5.7 mg/1.4 mg Starting dose 1.4 mg/0.36 mg Highest dose 5.7 mg/1.4 mg on Day 1
  • Start with 1.4 mg/0.36 mg, then remainder of up to 4.2 mg/1.08 mg in doses of 1 to 2 tablets of 1.4 mg/0.36 mg at 1.5 to 2 hour intervals

Good to know

Some patients may tolerate up to 3 x 1.4 mg/0.36 mg as a single, second dose

Zubsolv is a brand name for this medicine. See Zubsolv’s full dosing instructions on DailyMed →

Adults dependent on short-acting opioids such as heroin · Zubsolv 11.4 mg/2.9 mg Highest dose 11.4 mg/2.9 mg once a day
  • A single daily dose of up to 11.4 mg/2.9 mg

Zubsolv is a brand name for this medicine. See Zubsolv’s full dosing instructions on DailyMed →

Adults · Zubsolv 2.9 mg/0.71 mg Dose 2.9/0.71 mg
  • Generally in the range of 2.9 mg/0.71 mg to 17.2 mg/4.2 mg per day, based on clinical response

Zubsolv is a brand name for this medicine. See Zubsolv’s full dosing instructions on DailyMed →

See the Full Dosing Instructions on DailyMed →

Suboxone

Opioid dependence
Adults dependent on short-acting opioids such as heroin · Day 1 Starting dose 2 mg/0.5 mg or 4 mg/1 mg Highest dose 8 mg/2 mg on Day 1
  • Up to 8 mg/2 mg buprenorphine and naloxone sublingual film, starting with 2 mg/0.5 mg or 4 mg/1 mg and titrating upwards in 2 or 4 mg increments of buprenorphine at approximately 2-hour intervals
Adults dependent on short-acting opioids such as heroin · Day 2 Highest dose 16 mg/4 mg once a day
  • A single daily dose of up to 16 mg/4 mg buprenorphine and naloxone sublingual film
Adults · Maintenance dose Dose 4/1 mg
  • Generally in the range of 4 mg/1 mg to 24 mg/6 mg per day, based on clinical response, as a single daily dose

What a maintenance dose is: The regular ongoing dose taken to keep a steady, effective amount of medicine in the body over time.

See the Full Dosing Instructions on DailyMed →

Side Effects

Common side effects seen with this medicine include:

Common side effects

  • Headache
  • Nausea and vomiting
  • Constipation
  • Sweating
  • Trouble sleeping (insomnia)
  • Pain
  • Withdrawal symptoms
  • Numbness, redness or soreness in the mouth or tongue
  • Swelling in the hands or feet

When to get medical help

  • Call 911 or get emergency help right away for a known or suspected overdose, such as very slow or shallow breathing, extreme sleepiness or pinpoint pupils.
  • Get help right away for signs of a severe allergic reaction, such as hives, swelling, wheezing or trouble breathing.
  • Call your doctor if you have yellowing of the skin or eyes, dark urine or other signs of liver problems.
  • Call your doctor if you have nausea, vomiting, loss of appetite, severe tiredness, weakness, dizziness or low blood pressure, which can be signs of adrenal insufficiency.
  • Seek help for signs of serotonin syndrome if you take other serotonin-affecting drugs.
  • Tell your dentist or doctor about dental problems such as tooth decay, broken teeth or tooth loss.

Warnings and Precautions

  • Breathing problems: Life-threatening slowed breathing and death can occur, especially with alcohol, benzodiazepines or other sedating drugs, or injection misuse.
  • Misuse: It can be abused like other opioids. Keep it secure.
  • Children: Accidental exposure can cause severe, possibly fatal, breathing problems.
  • Liver: Hepatitis and liver events have been reported. Liver tests are recommended.
  • Withdrawal: Stopping suddenly can cause withdrawal, so the dose is tapered gradually.
  • Adrenal insufficiency: Reported with opioids, more often after over a month of use.
  • Allergic reactions: Rash, hives, swelling and anaphylaxis have been reported.

Interactions

Several types of medicines can clash with this one:

  • Alcohol, benzodiazepines and other sedating drugs: dangerous breathing slowdown, coma and death.
  • CYP3A4 inhibitors (erythromycin, ketoconazole, ritonavir): raise buprenorphine levels.
  • CYP3A4 inducers (rifampin, carbamazepine, phenytoin): lower levels and may cause withdrawal.
  • Some HIV medicines (efavirenz, nevirapine, etravirine, delavirdine, atazanavir): may need dose monitoring.
  • Serotonin-affecting drugs: risk of serotonin syndrome.
  • MAO inhibitors: not recommended during use or within 14 days of stopping.
  • Muscle relaxants: greater breathing depression.
  • Diuretics: may work less well.
  • Anticholinergic drugs: urinary retention and severe constipation.

Interactions Listed in the FDA-Approved Label

From the Buprenorphine / Naloxone prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Benzodiazepines and other CNS depressants For example: alcohol
    What happensAdditive effects increase the risk of respiratory depression, profound sedation, coma, and death.
    What to doCessation of benzodiazepines or other CNS depressants is preferred in most cases; if concomitant use is warranted, strongly consider recommending or prescribing an opioid overdose reversal agent.
  • CYP3A4 inhibitors For example: erythromycin, ketoconazole, ritonavir
    What happensCan increase buprenorphine plasma concentration, resulting in increased or prolonged opioid effects.
    What to doConsider dosage reduction until stable drug effects are achieved and monitor for respiratory depression and sedation; if the inhibitor is stopped, consider increasing the dosage and monitor for withdrawal.
  • CYP3A4 inducers For example: rifampin, carbamazepine, phenytoin
    What happensCan decrease buprenorphine plasma concentration, potentially causing decreased efficacy or withdrawal syndrome.
    What to doConsider increasing the dosage until stable drug effects are achieved and monitor for withdrawal; if the inducer is stopped, consider dosage reduction and monitor for respiratory depression.
  • Antiretrovirals: NNRTIs (efavirenz, nevirapine, etravirine, delavirdine)
    What happensSignificant pharmacokinetic interactions have been shown, but did not result in significant pharmacodynamic effects.
    What to doMonitor the dose if NNRTIs are added to chronic buprenorphine and naloxone treatment.
  • Antiretrovirals: protease inhibitors (atazanavir, ritonavir)
    What happensAtazanavir with or without ritonavir raised buprenorphine levels and caused increased sedation and symptoms of opioid excess; other PIs had little effect.
    What to doMonitor patients and reduce the dose if warranted.
  • Antiretrovirals: NRTIs
    What happensThey do not appear to induce or inhibit the P450 enzyme pathway, so no interactions with buprenorphine are expected.
    What to doNone
  • Serotonergic drugs (SSRIs, SNRIs, TCAs, triptans, mirtazapine, trazodone, tramadol, MAO inhibitors)
    What happensConcomitant use with opioids has resulted in serotonin syndrome.
    What to doCarefully observe the patient, particularly at initiation and dose adjustment; discontinue if serotonin syndrome is suspected.
  • Monoamine oxidase inhibitors (MAOIs)
    What happensInteractions with opioids may manifest as serotonin syndrome or opioid toxicity.
    What to doUse is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.
  • Muscle relaxants (cyclobenzaprine, metaxalone)
    What happensBuprenorphine may enhance neuromuscular blocking action and increase respiratory depression.
    What to doMonitor for respiratory depression and decrease the dosage of either drug as necessary; strongly consider an opioid overdose reversal agent.
  • Diuretics
    What happensOpioids can reduce the efficacy of diuretics by inducing release of antidiuretic hormone.
    What to doMonitor for diminished diuresis and/or effects on blood pressure and increase the diuretic dosage as needed.
Read the label’s full interactions text

7 DRUG INTERACTIONS Table 4 includes clinically significant drug interactions with buprenorphine and naloxone sublingual film. Table 4. Clinically Significant Drug Interactions Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. Intervention: Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In some cases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate. Before co-prescribing benzodiazepines for anxiety or insomnia, ensure that patients are appropriately diagnosed and consider alternative medications and non-pharmacologic treatments. If concomitant use is warranted, strongly consider recommending or prescribing an opioid overdose reversal agent, as is recommended for all patients on buprenorphine treatment for opioid use disorder. Examples: Alcohol, benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), and other opioids. Inhibitors of CYP3A4 Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of buprenorphine and naloxone sublingual film is achieved.

Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Do not use if allergic to buprenorphine or naloxone.
  • Tell your prescriber about lung or breathing problems.
  • Tell your prescriber about liver disease or hepatitis. It is not recommended in severe liver impairment and may not suit moderate impairment.
  • Tell your prescriber if you are pregnant. Newborns may have withdrawal (NOWS), which is treatable, and the dose may need adjusting during pregnancy.
  • Buprenorphine passes into breast milk.
  • Older adults should be monitored for sedation and slowed breathing.
  • Keep it away from children.

Overdose

Overdose can cause pinpoint pupils, sedation, low blood pressure, low blood sugar, slowed breathing and death. Call 911 right away. Treatment focuses on supporting breathing, and an opioid overdose reversal agent may help, though higher or repeated doses may be needed and long monitoring is important.

Half-Life and How Your Body Processes It

Buprenorphine is about 96% protein bound and is broken down mainly by the CYP3A4 enzyme. It leaves the body through urine and feces. Its half-life is about 24 to 42 hours, and naloxone's is about 2 to 12 hours, based on the film. Film and tablet products can deliver different amounts, and Zubsolv differs from Suboxone tablets, so strengths are not directly interchangeable.

Storage

Store at 20° to 25°C (68° to 77°F). Store buprenorphine and naloxone sublingual film securely and dispose of properly .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Buprenorphine / Naloxone: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Buprenorphine / Naloxone — the kind of thing our pharmacy team would talk through with you at the counter.

What is this medicine for?

It treats opioid dependence. It works best as part of a full plan that includes counseling and support.

How do I take it?

You take it once a day, letting it dissolve under your tongue. The film may also be placed inside the cheek. Don't chew or swallow it unless your pharmacist or prescriber says otherwise, and follow your label exactly.

Can I drink alcohol or take my anxiety or sleep medicine with it?

Please don't without talking to your prescriber. Alcohol, benzodiazepines and other sedating drugs can slow your breathing dangerously. Tell every provider you see that you take this medicine.

What side effects should I expect?

Headache, nausea, constipation, sweating, trouble sleeping and mouth soreness or numbness are common. Call your doctor if you have yellow skin or eyes, a rash or hives, or signs of withdrawal that don't settle. Call 911 for slow breathing or extreme sleepiness.

Should I keep naloxone at home?

Yes, it's a good idea to ask about it. Naloxone can reverse an overdose, and your prescriber is encouraged to consider it. Still call 911 even if you use it.

Is it safe in pregnancy or around kids?

Talk to your doctor if you're pregnant. Babies may have withdrawal that can be treated, and untreated opioid addiction carries its own risks. Keep your medicine locked up and away from children, since even a small amount can cause dangerous breathing problems.

Is buprenorphine / naloxone available over the counter?

No. Buprenorphine / naloxone is a prescription medicine: every buprenorphine / naloxone product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

Is buprenorphine / naloxone a controlled substance?

Yes — buprenorphine / naloxone is a federally controlled substance (Schedule III) in the United States, so how it is prescribed, refilled and dispensed is regulated by the DEA.

When was buprenorphine / naloxone first available?

The earliest FDA record we hold for buprenorphine / naloxone is from 2010: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when buprenorphine / naloxone was first used.

Who makes buprenorphine / naloxone?

29 companies currently list buprenorphine / naloxone products in the FDA's NDC Directory, including Bryant Ranch Prepack, Camber Pharmaceuticals, Inc., Edenbridge Pharmaceuticals LLC.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of buprenorphine / naloxone?

Buprenorphine / naloxone is the generic name. Its brand names are Suboxone, Zubsolv and Bunavail. Generic versions are listed under the name buprenorphine / naloxone.

What is the generic name of Suboxone?

The generic name of Suboxone is buprenorphine / naloxone. A generic name is the name of the active ingredients, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is buprenorphine / naloxone?

Buprenorphine / naloxone belongs to the drug class Opioid Antagonist and Partial Opioid Agonist, its established pharmacologic class on the FDA label.

Is there a generic version of buprenorphine / naloxone?

Yes. FDA-approved generic versions of buprenorphine / naloxone are listed in the FDA's National Drug Code Directory. A listing does not prove that every pharmacy stocks one, so your pharmacy can tell you which version it carries.

What strengths does buprenorphine / naloxone come in?

Buprenorphine / naloxone is listed in the FDA's National Drug Code Directory in these forms and strengths. Sublingual tablet (under the tongue): 0.7 mg/0.18 mg, 1.4 mg/0.36 mg, 2 mg/0.5 mg, 2.9 mg/0.71 mg, 5.7 mg/1.4 mg, 8 mg/2 mg, 8.6 mg/2.1 mg and 11.4 mg/2.9 mg. Sublingual film (inside the cheek, under the tongue): 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg and 12 mg/3 mg. A listing does not mean every pharmacy stocks every strength.

How much does buprenorphine / naloxone cost?

What you pay depends on your insurance, your pharmacy and the strength you take. As a benchmark, pharmacies paid a national average of $0.54 to $0.74 per generic sublingual tablet across 6 strengths, $5.26 to $21.04 per sublingual tablet of brand-name Zubsolv across 6 strengths, $1.33 to $4.13 each for the generic sublingual film across 12 strengths and $4.78 to $17.16 each for the sublingual film of brand-name Suboxone across 4 strengths as of November 18, 2026 (CMS's NADAC survey). That is the pharmacy's own cost for the medicine, not the price at the counter. The pharmacy prices section of this page lists every strength priced.

Where can I read the buprenorphine / naloxone prescribing information (package insert)?

The full FDA-approved prescribing information for buprenorphine / naloxone, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Orexo US, Inc.'s, revised Dec 27, 2025, and links to it on DailyMed.

Can you crush buprenorphine / naloxone?

Some forms of buprenorphine / naloxone are on our Do Not Crush list of tablets and capsules that should not be crushed or chewed: Buprenorphine hydrochloride-naloxone hydrochloride (tablet, sublingual); Zubsolv (tablet, sublingual). A form made to dissolve under the tongue or in the cheek is meant to be absorbed there. A form that is not on the list may still come with its own instructions, so check the label and ask your pharmacist before you crush, split or open any medicine. Each listed form’s reason and instructions are on our Do Not Crush list.

Is buprenorphine / naloxone gluten free?

No buprenorphine / naloxone label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten. We read the FDA labels of 102 buprenorphine / naloxone products from 29 companies. Of those, 13 name a starch, dextrin or maltodextrin without saying where it comes from, so for those the answer is "source unclear", not "no". A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's buprenorphine / naloxone by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See buprenorphine / naloxone inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Buprenorphine / Naloxone

Skip the scrolling. Ask in your own words and get an answer from Buprenorphine / Naloxone’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Buprenorphine / Naloxone’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Buprenorphine / Naloxone on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Buprenorphine / Naloxone Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Buprenorphine / Naloxone Forms and Strengths (How It Comes)

Buprenorphine / Naloxone comes in 2 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Buprenorphine / Naloxone inactive ingredients by manufacturer.

Sublingual tablet

Under the tongue
Brands Zubsolv (2013)
How this form is used
What it may be used for
  • Buprenorphine and naloxone sublingual tablets are used for maintenance treatment of opioid dependence, with counseling and psychosocial support.
  • Zubsolv is used for treatment of opioid dependence, with counseling and psychosocial support.
Important instructions
  • Buprenorphine and naloxone sublingual tablets are placed under the tongue as a single daily dose.
  • Zubsolv is taken under the tongue as a single daily dose after induction, and is given in divided doses at the start of treatment.
  • Zubsolv has different bioavailability from Suboxone tablets, so milligram strengths of different products are not directly comparable.
Available strengths 12 strengths
Show 6 more strengths Show fewer strengths
72 FDA-listed product records ⓘ

Sublingual film

Inside the cheek · Under the tongue
Brands Suboxone (the first brand, 2002)
How this form is used
What it may be used for
  • Suboxone sublingual film is used for treatment of opioid dependence, as part of a complete plan with counseling and psychosocial support.
Important instructions
  • Suboxone sublingual film is given as a single daily dose.
  • Suboxone sublingual film induction should start when clear signs of withdrawal are present, and it is given in divided doses at the start of treatment.
  • Your prescriber should strongly consider recommending an opioid overdose reversal agent when Suboxone film is started or renewed.
Available strengths 12 strengths
Show 6 more strengths Show fewer strengths
31 FDA-listed product records ⓘ

Buprenorphine / Naloxone on the U.S. Market: Products, Makers and Brands

How Buprenorphine / Naloxone appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

29 companies list 102 Buprenorphine / Naloxone product records with the FDA, mostly as sublingual tablet, sublingual film; the earliest marketing or approval year on record is 2010. Brand names in the directory today include Suboxone and Zubsolv; the rest are generics.

2
Dose forms ⓘ
29
Labelers (makers, repackagers, distributors)
3
Brand names ⓘ
102
FDA-listed product records ⓘ
2010
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Bryant Ranch Prepack15%
Camber Pharmaceuticals, Inc.6%
Edenbridge Pharmaceuticals LLC.6%
Orexo US, Inc.6%
Clinical Solutions Wholesale, LLC5%
Redpharm Drug5%
Other makers58%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely Buprenorphine / Naloxone Is Used (Medicaid Data)

How many Buprenorphine / Naloxone prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

6,982,290
Medicaid prescriptions filled (Q1–Q4 2025)
$1.17B paid by Medicaid, before rebates

How commonly is Buprenorphine / Naloxone prescribed? Of the 1,682 medications we measure, Buprenorphine / Naloxone ranks #21 by Medicaid prescriptions — more than 99% of them.

Where Buprenorphine / Naloxone ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Buprenorphine / Naloxone product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 8 mg / 2 mg sublingual film is the most-dispensed Buprenorphine / Naloxone product — about 52% of these Medicaid prescriptions.

buprenorphine 8 MG / naloxone 2 MG Sublingual Film Most dispensed

3,642,176 Medicaid prescriptions (Q1–Q4 2025) 52% of Buprenorphine / Naloxone prescriptions shown $827.3M paid by Medicaid, before rebates ≈ $227 per prescription, before rebates

5 of 22 listed NDCs had Medicaid claims. RxNorm 1010604

buprenorphine 8 MG / naloxone 2 MG Sublingual Tablet

2,081,526 Medicaid prescriptions (Q1–Q4 2025) 30% of Buprenorphine / Naloxone prescriptions shown $96.8M paid by Medicaid, before rebates ≈ $46 per prescription, before rebates

12 of 89 listed NDCs had Medicaid claims. RxNorm 351267

buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet

351,481 Medicaid prescriptions (Q1–Q4 2025) 5% of Buprenorphine / Naloxone prescriptions shown $11.8M paid by Medicaid, before rebates ≈ $34 per prescription, before rebates

11 of 39 listed NDCs had Medicaid claims. RxNorm 351266

buprenorphine 12 MG / naloxone 3 MG Sublingual Film

329,299 Medicaid prescriptions (Q1–Q4 2025) 5% of Buprenorphine / Naloxone prescriptions shown $123.5M paid by Medicaid, before rebates ≈ $375 per prescription, before rebates

5 of 20 listed NDCs had Medicaid claims. RxNorm 1307061

buprenorphine 4 MG / naloxone 1 MG Sublingual Film

239,955 Medicaid prescriptions (Q1–Q4 2025) 3% of Buprenorphine / Naloxone prescriptions shown $45.4M paid by Medicaid, before rebates ≈ $189 per prescription, before rebates

5 of 18 listed NDCs had Medicaid claims. RxNorm 1307056

buprenorphine 2 MG / naloxone 0.5 MG Sublingual Film

222,662 Medicaid prescriptions (Q1–Q4 2025) 3% of Buprenorphine / Naloxone prescriptions shown $22.5M paid by Medicaid, before rebates ≈ $101 per prescription, before rebates

5 of 22 listed NDCs had Medicaid claims. RxNorm 1010600

buprenorphine 5.7 MG / naloxone 1.4 MG Sublingual Tablet

63,391 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine / Naloxone prescriptions shown $24M paid by Medicaid, before rebates ≈ $378 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1431102

buprenorphine 8.6 MG / naloxone 2.1 MG Sublingual Tablet

24,268 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine / Naloxone prescriptions shown $13.1M paid by Medicaid, before rebates ≈ $540 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1597573

buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet

10,711 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine / Naloxone prescriptions shown $3.3M paid by Medicaid, before rebates ≈ $310 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1666338

buprenorphine 11.4 MG / naloxone 2.9 MG Sublingual Tablet

8,884 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine / Naloxone prescriptions shown $4.9M paid by Medicaid, before rebates ≈ $556 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1597568

buprenorphine 1.4 MG / naloxone 0.36 MG Sublingual Tablet

5,312 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine / Naloxone prescriptions shown $818,484 paid by Medicaid, before rebates ≈ $154 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1431076

buprenorphine 0.7 MG / naloxone 0.18 MG Sublingual Tablet

2,625 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine / Naloxone prescriptions shown $427,536 paid by Medicaid, before rebates ≈ $163 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1864412

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 49 of the 222 listed Buprenorphine / Naloxone NDCs had Medicaid claims.

Compare Buprenorphine / Naloxone Products

A representative set of FDA-listed product records for Buprenorphine / Naloxone — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 102 of 102 products — FDA National Drug Code Directory. See every product, package size and price: browse all 102 Buprenorphine / Naloxone NDCs →

Buprenorphine / Naloxone Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Buprenorphine / Naloxone recalls since July 2021.

✅No Buprenorphine / Naloxone recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Buprenorphine / Naloxone in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one exact combination of ingredients (MIN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. A different combination is a different concept with its own page.

Dose forms
3
Strengths
15
Forms in current FDA listings
2 of 3
In current FDA listings No current FDA listing
Multiple ingredients (MIN) Buprenorphine / Naloxone RxCUI 352364
  1. Dose form (SCDF) Buccal Film RxCUI 1542389
    No current FDA listing
    Its 3 strengths (SCD)
    • buprenorphine 2.1 mg / naloxone 0.3 mg RxCUI 1542390
    • buprenorphine 4.2 mg / naloxone 0.7 mg RxCUI 1544851
    • buprenorphine 6.3 mg / naloxone 1 mg RxCUI 1544854
  2. Dose form (SCDF) Sublingual Film RxCUI 2269593
    In current FDA listings
  3. Dose form (SCDF) Sublingual Tablet RxCUI 378762
    In current FDA listings

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

What Buprenorphine / Naloxone Costs Pharmacies (NADAC Benchmark)

What pharmacies pay to buy Buprenorphine / Naloxone: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.

How the Pharmacy Price Has Changed

Pick a form, the generic or the brand, and a strength to see how its price has changed since Nov 2023.

Form
Version
Strength

For the generic BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE 0.5 mg sublingual film, pharmacies paid an average of $1.33 each as of Nov 18, 2026, down 21% from $1.69 a year earlier.

What pharmacies pay now
$1.33
each, as of Nov 18, 2026
Last 4 weeks
Down 3.8%
from $1.39 on Oct 21, 2026
Last 12 months
Down 21%
from $1.69 on Nov 19, 2025
Lowest and highest since Nov 2023
$1.24 to $2.26
each

Each step is one weekly survey. Arrow keys on the chart move week by week.
See the numbers, month by month
Generic BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE 0.5 mg sublingual film: the average pharmacy price each, the last survey of each month
MonthPharmacy price
Nov 2026$1.33
Oct 2026$1.39
Sep 2026$1.39
Aug 2026$1.38
Jul 2026$1.31
Jun 2026$1.28
May 2026$1.30
Apr 2026$1.31
Mar 2026$1.29
Feb 2026$1.34
Jan 2026$1.33
Dec 2025$1.56
Nov 2025$1.69
Oct 2025$1.91
Sep 2025$1.90
Aug 2025$1.92
Jul 2025$1.87
Jun 2025$1.86
May 2025$1.89
Apr 2025$1.89
Mar 2025$1.88
Feb 2025$1.79
Jan 2025$1.61
Dec 2024$1.61
Nov 2024$1.24
Oct 2024$1.88
Sep 2024$2.04
Aug 2024$2.03
Jul 2024$1.38
Jun 2024$1.89
May 2024$1.41
Apr 2024$1.41
Mar 2024$2.18
Feb 2024$2.06
Jan 2024$2.14
Dec 2023$2.16
Nov 2023$2.17
See all 28 prices in a table
FormStrengthVersion What pharmacies pay
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE 0.5 mg Generic $1.33 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg Generic $1.33 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg Suboxone (brand) $4.78 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg Generic $1.33 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE 1 mg Generic $2.44 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE HYDROCHLORIDE 1 mg Generic $2.44 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE HYDROCHLORIDE 1 mg Suboxone (brand) $8.58 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 1 mg Generic $2.44 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE 2 mg Generic $1.93 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg Generic $1.93 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg Suboxone (brand) $8.58 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg Generic $1.93 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE 3 mg Generic $4.13 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE 3 mg Generic $4.13 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE 3 mg Suboxone (brand) $17.16 each NDC details & price history
Sublingual film · Buccal, Sublingual BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 3 mg Generic $4.13 each NDC details & price history
Sublingual tablet · Sublingual BUPRENORPHINE HYDROCHLORIDE 0.7 mg/1; NALOXONE HYDROCHLORIDE 0.18 mg Zubsolv (brand) $5.26 per tablet NDC details & price history
Sublingual tablet · Sublingual BUPRENORPHINE HYDROCHLORIDE 1.4 mg/1; NALOXONE HYDROCHLORIDE 0.36 mg Zubsolv (brand) $5.26 per tablet NDC details & price history
Sublingual tablet · Sublingual BUPRENORPHINE 2 mg/1; NALOXONE 0.5 mg Generic $0.539 per tablet NDC details & price history
Sublingual tablet · Sublingual BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg Generic $0.539 per tablet NDC details & price history
Sublingual tablet · Sublingual BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg Generic $0.539 per tablet NDC details & price history
Sublingual tablet · Sublingual BUPRENORPHINE HYDROCHLORIDE 2.9 mg/1; NALOXONE HYDROCHLORIDE 0.71 mg Zubsolv (brand) $10.52 per tablet NDC details & price history
Sublingual tablet · Sublingual BUPRENORPHINE HYDROCHLORIDE 5.7 mg/1; NALOXONE HYDROCHLORIDE 1.4 mg Zubsolv (brand) $10.55 per tablet NDC details & price history
Sublingual tablet · Sublingual BUPRENORPHINE 8 mg/1; NALOXONE 2 mg Generic $0.735 per tablet NDC details & price history
Sublingual tablet · Sublingual BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg Generic $0.735 per tablet NDC details & price history
Sublingual tablet · Sublingual BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg Generic $0.735 per tablet NDC details & price history
Sublingual tablet · Sublingual BUPRENORPHINE HYDROCHLORIDE 8.6 mg/1; NALOXONE HYDROCHLORIDE 2.1 mg Zubsolv (brand) $15.81 per tablet NDC details & price history
Sublingual tablet · Sublingual BUPRENORPHINE HYDROCHLORIDE 11.4 mg/1; NALOXONE HYDROCHLORIDE 2.9 mg Zubsolv (brand) $21.04 per tablet NDC details & price history
Why it helps: it shows whether the drug itself is cheap or costly, and whether a cash price you are quoted is in a reasonable range. What you pay also depends on your insurance and pharmacy.

Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.

Buprenorphine / Naloxone Brand Names

Buprenorphine / Naloxone has 3 brand names on record: Suboxone, Zubsolv and Bunavail. Suboxone and Zubsolv are in the FDA’s product directory today; Bunavail is not. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Suboxone the first brand, 2002 Zubsolv 2013 Bunavail 2014, discontinued

Who Makes Buprenorphine / Naloxone: Manufacturers and Labelers

29 companies list Buprenorphine / Naloxone products with the FDA. By number of product records, the largest are Bryant Ranch Prepack, Camber Pharmaceuticals, Inc., Edenbridge Pharmaceuticals LLC.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Bryant Ranch Prepack 15 Camber Pharmaceuticals, Inc. 6 Edenbridge Pharmaceuticals LLC. 6 Orexo US, Inc. 6 Clinical Solutions Wholesale, LLC 5 Redpharm Drug 5 Alvogen Inc. 4 Aveva Drug Delivery Systems Inc. 4 Dr.Reddys Laboratories Inc 4 Indivior Inc. 4 Ingenus Pharmaceuticals, Llc 4 Mylan Pharmaceuticals Inc. 4 Remedyrepack Inc. 3 Unit Dose Solutions, Inc. 3 Accord Healthcare, Inc 2 Actavis Pharma, Inc. 2 American Health Packaging 2 Amneal Pharmaceuticals LLC 2 Ascend Laboratories, LLC 2 AvPAK 2 Golden State Medical Supply, Inc. 2 Hikma Pharmaceuticals USA Inc. 2 Lannett Company, Inc. 2 Major Pharmaceuticals 2

…and 5 more on the FDA NDC directory.

Sources for This Buprenorphine / Naloxone Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Dec 27, 2025, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Buprenorphine / Naloxone.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 55 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
55
Finished products in the current FDA directory
102
Companies listing them (makers, repackagers, distributors)
29
FDA labeler codes behind them ⓘ
31
Linked representative label ⓘ
Orexo US, Inc.
Linked label effective
Dec 27, 2025
Composite sections available
24
Linked SPL Set ID
5f5cfcfe-d52b-49e6-8fe4-550477332dd2
Linked SPL Document ID
8c67e97f-118f-4226-972a-a9031ef6f5ce
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Orexo US, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →